Andrew Ball, Chief Executive Officer, brings over 20 years of global leadership experience and value creation in the life sciences industry, with a successful track record in technological and commercial development of assay platforms and services, spanning startups to large multinationals. Prior to joining SeromYx in 2025, he served as Vice President, Assay Development Platforms at Abcam, a Danaher company, where he led a global R&D organization developing and commercializing immunoassays, cell-based assays, antibody conjugates, recombinant proteins and contract assay services.  He has also held roles as VP of Assay Development at Quanterix, developing ultrasensitive assays for neurodegenerative disease and immuno-oncology; as VP of R&D at Quad Technologies, a cell and gene therapy startup acquired by Bio-Techne, and has served in a variety of innovation and strategic leadership roles at MilliporeSigma. He studied at Ulster University and held post-doctoral positions at Louisiana State University and the Sanford-Burnham Medical Institute.

Dr. Lenny Moise, VP Research, manages client projects and scientific development of the SeromYx Systems Serology platform for clinical research and drug discovery in infectious disease, immuno-oncology, autoimmunity and neurology. Prior to joining SeromYx, Lenny was Director of Vaccine Research at EpiVax, where he used immunoinformatic approaches to design and develop vaccines that exploit T cell immunity for viral and bacterial infectious diseases and cancer and to screen and de-risk biologic immunogenicity. Over that time, he studied T cell responses to vaccines and developed immunoinformatic tools as a member of the faculty of the Institute for Immunology and Informatics at the University of Rhode Island and the Center for Vaccines and Immunology at the University of Georgia. Lenny trained in structure-function analysis of snake toxin-ion channel interactions using structural, biochemical, and electrophysiological methods and holds a Bachelor of Science with honors and a doctorate from Brown University.

Briana Dougherty, Senior Director of Operations, oversees multiple areas at SeromYx including Facilities, Ordering and Procurement, Quality and IT. In this role, she has implemented many internal processes and procedures and led SeromYx’s GCLP accreditation process. Prior to joining SeromYx, Briana has spent over 10 years working at multiple CAP/CLIA certified molecular diagnostic testing companies in laboratory operations and quality control. Initially starting out as a laboratory technologist, Briana spent over 5 years in quality control before moving into laboratory operations and facility management. Briana holds a B.S. with honors in Biotechnology from Worcester Polytechnic Institute.

Dr. Shashi Jatiani, Director Research, leads internal R&D, external collaborations for the scientific development of the SeromYx Systems therapeutic antibody platform across therapeutic areas with a focus on oncology, immuno-oncology, and autoimmunity. He speaks on behalf of the company at global conferences and drives technical discussions with clients. In his previous roles in the biotech industry, Shashi served as lead biologist in cross functional teams delivering developmental candidates for solid tumor indications. He led interdisciplinary industry-sponsored small molecule oncology drug discovery campaigns as a faculty member of the Departments of Oncological Sciences and Pharmacological Sciences at Mount Sinai Medical Center and developed deep expertise in cancer therapeutics during his postdoctoral training at the Temple University School of Medicine. He holds a Doctorate in Molecular Biology from the Tata Institute for Fundamental Research, University of Mumbai, where he studied the role of large G proteins in endocytosis and received a Masters of Science degree in Microbiology from the Maharaja Sayajiroa University of Baroda.

Abigail Harris, Business Development Manager, drives strategic growth, sales, and marketing initiatives at SeromYx Systems, expanding the company’s presence in antibody therapeutics and vaccine development. In this role, she manages key industry partnerships, assists with early-stage project discussions, and presents SeromYx’s offerings at conferences and meetings. Prior to joining SeromYx, she was a Business Development Manager at Altis Biosystems, a CRO start-up specializing in next-generation in-vitro models for gastrointestinal research. There, she worked closely with small molecule and antibody therapeutic drug developers, securing new clients, driving revenue growth, and supporting marketing initiatives. Abigail holds a Bachelors of Science degree in Biology from the University of New Hampshire.